跳至主要内容
临床试验/NCT01391286
NCT01391286已完成3 期

A Multicenter, Double-masked, Randomized, Parallel-group Study Assessing the Safety and Efficacy of Once-daily Application of Bimatoprost Solution 0.03% Compared to Vehicle to Treat Chemotherapy-induced Hypotrichosis of the Eyelashes in Japanese Subjects

Allergan0 个研究点目标入组 36 人开始时间: 2011年7月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Allergan
入组人数
36
主要终点
Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA)

研究概览

简要总结

This study will evaluate the safety and efficacy of bimatoprost solution 0.03% compared with vehicle in Japanese adults with hypotrichosis of the eyelashes following chemotherapy treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Have inadequate eyelashes due to chemotherapy treatment
  • Treated for solid tumors such as breast or colorectal cancer in early stages where the cancer has not spread outside the primary organ (eg, stage 1, 2 or 3a for breast cancer)
  • Have completed chemotherapy treatment for at least 4 weeks but not more than 24 weeks and all side effects related to chemotherapy are recovered, improved or maintained, with the exception of hair loss

排除标准

  • Any disease/infection/abnormality of the eye or area around the eye
  • Any ocular surgery within 3 months or anticipated need for ocular surgery during the study
  • Any permanent eyeliner or implants of any kind or anticipated use of false eyelashes
  • Any semi-permanent eyelash tint, dye, curl or eyelash extension application within 3 months
  • Use of any over-the-counter eyelash growth product within 6 months or any use of prescription eyelash growth products
  • Use of treatments which may affect hair growth (eg, minoxidil) within 6 months except for prior chemotherapy

研究组 & 干预措施

bimatoprost solution 0.03%

Experimental

One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.

干预措施: bimatoprost solution 0.03% (Drug)

bimatoprost vehicle solution

Placebo Comparator

One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.

干预措施: bimatoprost vehicle solution (Drug)

结局指标

主要结局

Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA)

时间窗: Baseline, Month 4

The investigator evaluated the patient's eyelash prominence using the GEA 4-point scale: 1= minimal, 2= moderate, 3= marked and 4= very marked at Baseline and Month 4. At least a 1-grade increase in the GEA score from Baseline indicated improvement.

次要结局

  • Change From Baseline in Eyelash Length as Measured by Digital Image Analysis (DIA)(Baseline, Month 4)
  • Change From Baseline in Eyelash Thickness as Measured by DIA(Baseline, Month 4)
  • Change From Baseline in Eyelash Darkness as Measured by DIA(Baseline, Month 4)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验